KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Change in Acquisitions & Divestments (2017 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Change in Acquisitions & Divestments for 16 consecutive years, with $222.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Acquisitions & Divestments fell 49.88% year-over-year to $222.0 million, compared with a TTM value of $1.8 billion through Dec 2025, up 14.67%, and an annual FY2025 reading of $1.8 billion, up 14.67% over the prior year.
  • Change in Acquisitions & Divestments was $222.0 million for Q4 2025 at Alnylam Pharmaceuticals, down from $1.5 billion in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $1.6 billion in Q3 2022 and bottomed at -$1.5 billion in Q4 2022.
  • Average Change in Acquisitions & Divestments over 5 years is $249.3 million, with a median of $369.4 million recorded in 2023.
  • The sharpest move saw Change in Acquisitions & Divestments crashed 206.91% in 2022, then soared 3872.55% in 2023.
  • Year by year, Change in Acquisitions & Divestments stood at $1.4 billion in 2021, then plummeted by 206.91% to -$1.5 billion in 2022, then grew by 26.38% to -$1.1 billion in 2023, then soared by 139.15% to $443.0 million in 2024, then tumbled by 49.88% to $222.0 million in 2025.
  • Business Quant data shows Change in Acquisitions & Divestments for ALNY at $222.0 million in Q4 2025, $1.5 billion in Q3 2025, and -$466.3 million in Q2 2025.